Effervescent Patents (Class 424/466)
  • Patent number: 10314801
    Abstract: The invention provides coated particles with a taste-masked drug substance. The particles comprise a core with the agglomerated active ingredient and a coating comprising a triglyceride and a surfactant. The particles exhibit rapid drug release and a stable release profile. Moreover, the invention provides a hot-melt coating method for manufacturing such particles, and pharmaceutical compositions comprising the particles. The method allows the coating of core particles at moderate temperatures, thereby preventing the degradation of the thermolabile active ingredient.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: June 11, 2019
    Assignee: HERMES ARZNEIMITTEL GMBH
    Inventors: Klaus Dandl, Detlev Haack, Karin Becker, Andreas Zimmer, Claudia Lang, Sharareh Salar Behzadi
  • Patent number: 10258576
    Abstract: The present invention relates to a particulate material and a solid dosage form notably tablets comprising a regularly shaped calcium-containing compound such as a calcium salt as a therapeutically and/or prophylactically active substance and a pharmaceutically acceptable sugar alcohol such as, e.g., sorbitol and/or isomalt that has a micro structure as evidenced by SEM. The invention also relates to a process for the preparation of the particulate material and solid dosage form. The process involves agglomeration of the calcium-containing compound and the pharmaceutically acceptable sugar alcohol by means of roller compaction. The particulate material obtained by roller compaction is suitable for use in the further processing of the particulate material into e.g. tablets such as chewing tablets.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: April 16, 2019
    Assignee: Takeda AS
    Inventors: Jacob Mathiesen, Carsten Martini Nielsen, Peder Mohr Olsen, Poul Egon Bertelsen
  • Patent number: 10232622
    Abstract: Disclosed is a water-repellent film 102 including a substrate 100, and a water-repellent organic material provided on the substrate 100, in which a plurality of regions having different concentrations of the water-repellent organic material are formed, and each of the regions having different concentrations continuously exists in a film thickness direction from a boundary surface with respect to the substrate to a surface of the water-repellent film. Preferably, in the regions having different concentrations, a region having a relatively higher concentration 102a is formed into the shape of a column, and a region having a relatively lower concentration 102b than that of the columnar region exists around the columnar region.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: March 19, 2019
    Assignee: FUJIFILM Corporation
    Inventor: Hiroki Uchiyama
  • Patent number: 10092505
    Abstract: The present invention provides an oral film-form base which has a rapid dissolution profile in the mouth and sufficient film strength, and gives an improved taking property by foaming in the mouth. The oral film-form base includes an edible polymer soluble both in water and in an organic solvent having a solubility parameter of 9.7 or higher, a foaming agent, and an auxiliary foaming agent, wherein the foaming agent is foamable in the presence of water, and the foaming agent and the auxiliary foaming agent each are insoluble in the organic solvent, have an average particle size of 0.1 to 60 ?m, and are included in particle states.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: October 9, 2018
    Assignee: NITTO DENKO CORPORATION
    Inventors: Daisuke Asari, Mitsuhiko Hori, Takuya Shishido
  • Patent number: 9908675
    Abstract: Disclosed herein are water-soluble films and resulting packets including a water-soluble film coated by a powder, wherein the powder includes a mixture of a powdered lubricant and an active agent. Optionally, the active agent may be encapsulated, e.g. microencapsulated, for release of the active agent through mechanisms including, but not limited to, mechanical rupture, melt, ablation, dissolution, diffusion, biodegradation, or pH-controlled release. Active ingredients described include enzymes, oils, flavors, colorants, odor absorbers, fragrances, pesticides, fertilizers, activators, acid catalysts, metal catalysts, ion scavengers, bleaches, bleach components, fabric softeners and combinations thereof. Examples of packet fills include laundry detergents, bleach and laundry additives, fabric care, dishwashing, hard surface cleaning, beauty care, skin care, other personal care, and foodstuffs.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: March 6, 2018
    Assignee: MONOSOL, LLC
    Inventors: David M. Lee, Yashodhan S. Parulekar
  • Patent number: 9884014
    Abstract: There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 seconds forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insoluble and gastrosoluble polymers release not less than about 60% of the dose is in the stomach in about 30 minutes, thus maximizing the probability of achieving bioequivalence to the reference IR product having rapid onset of action (short Tmax). A process for preparing such compositions for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: February 6, 2018
    Assignee: ADARE PHARMACEUTICALS, INC.
    Inventor: Gopi M. Venkatesh
  • Patent number: 9821014
    Abstract: The present invention relates to complexes of beepollen and clay, as well as to their preparation methods and to their therapeutic uses or as a food supplement, a functional food, in human and animal healthcare.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: November 21, 2017
    Assignee: Laboratoire Beepratte
    Inventor: Alexandra Fregonese
  • Patent number: 9775807
    Abstract: The invention relates to solid medicinal forms containing at least one active ingredient and at least one pharmaceutically compatible, water soluble drying agent which is selected from the group consisting of trimagnesium dicitrate and/or calcium chloride, the solid medicinal form having a drying loss of at most 6% and a relative equilibrium moisture content of 25% or less. The invention also relates to solid medicinal forms containing a moisture-sensitive active ingredient and trimagnesium dicitrate.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: October 3, 2017
    Assignee: Losan Pharma GmbH
    Inventors: Peter Gruber, Dirk Spickermann
  • Patent number: 9757455
    Abstract: The present invention provides an oral delivery system for a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof with pharmacological, physiological or biochemical activity. The present invention particularly provides a swallow formulation comprising a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof which facilitates the rapid delivery of the therapeutic compound to the circulatory system.
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: September 12, 2017
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Michael Stephen Roberts, George Alexander Davidson, Ruoying Jiang, Geraldine Ann Elliott, Keivan Bezanehtak, Stephen Douglas Chandler, Greg Davey, Mantu Sarkar
  • Patent number: 9592195
    Abstract: A stable effervescent tablet, granule or powder composition free from excipients that may react with an effervescing organic acid component, comprising, an effective amount of a bisphosphonate bone resorption inhibitor, an effervescing organic acid component, an effervescing base component; wherein said composition is free of polyol binders and tableting lubricants; has a loss on drying of 0.25% (m/m) or less; has a complete disintegration time of no more than 180 seconds when placed in 3 to 8 fluid ounces of water at between 5-20° C.; and said bisphosphonate is incorporated as a micronized particle or by spray drying and is completely solubdised in water within 2 minutes without stirring.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: March 14, 2017
    Assignee: EffRx Pharmaceuticals SA
    Inventors: Marshall A. Hayward, Timo Schmidt
  • Patent number: 9572826
    Abstract: A composition for the treatment or prevention of a disorder resulting in hair loss comprises a cardiac glycoside as active principal.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: February 21, 2017
    Inventor: Elias Bouras
  • Patent number: 9492377
    Abstract: The present invention relates to an effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: November 15, 2016
    Assignee: PROBIOTICAL S.P.A.
    Inventors: Giovanni Mogna, Gian Paolo Strozzi, Luca Mogna
  • Patent number: 9452142
    Abstract: An oral dosage form for administration to an animal comprising a biologically utilizable form of calcium and an extended release system that maintains the calcium level in the animal's bloodstream at a substantially beneficial level for a defined period of time.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: September 27, 2016
    Assignee: Bayer HealthCare LLC
    Inventors: Pradnya Beke, Ashish Patel, Stephanie Petaway-Hickson
  • Patent number: 9427421
    Abstract: Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: August 30, 2016
    Assignee: ALPEX PHARMA S.A.
    Inventors: Federico Stroppolo, Gabriele Granata, Shahbaz S. Ardalan
  • Patent number: 9394092
    Abstract: Disclosed herein are water-soluble films and resulting packets including a water-soluble film coated by a powder, wherein the powder includes a mixture of a powdered lubricant and an active agent. Optionally, the active agent may be encapsulated, e.g. microencapsulated, for release of the active agent through mechanisms including, but not limited to, mechanical rupture, melt, ablation, dissolution, diffusion, biodegradation, or pH-controlled release. Active ingredients described include enzymes, oils, flavors, colorants, odor absorbers, fragrances, pesticides, fertilizers, activators, acid catalysts, metal catalysts, ion scavengers, bleaches, bleach components, fabric softeners and combinations thereof. Examples of packet fills include laundry detergents, bleach and laundry additives, fabric care, dishwashing, hard surface cleaning, beauty care, skin care, other personal care, and foodstuffs.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 19, 2016
    Assignee: MONOSOL, LLC
    Inventors: David M. Lee, Yashodhan S. Parulekar
  • Patent number: 9358295
    Abstract: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse by intake of alcohol.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: June 7, 2016
    Assignee: EGALET LTD.
    Inventors: Peter Holm Tygesen, Jan Martin Oevergaard, Joakim Oestman
  • Patent number: 9296753
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: March 29, 2016
    Assignee: Pharmacyclics LLC
    Inventors: Mark Smyth, Erick Goldman, David D. Wirth, Norbert Purro
  • Patent number: 9272033
    Abstract: The invention provides compositions for preventing or treating kidney disease comprising vitamin E, vitamin C, and a carotenoid and methods for preventing and treating kidney disease comprising administering such compositions to an animal susceptible to or suffering from kidney disease. In a preferred embodiment, the composition is admixed with one or more food ingredients to produce a food composition useful for preventing or treating kidney disease.
    Type: Grant
    Filed: April 19, 2006
    Date of Patent: March 1, 2016
    Assignee: HILL'S PET NUTRITION, INC.
    Inventors: Shiguang Yu, Timothy Arthur Allen
  • Patent number: 9198455
    Abstract: A carbon dioxide source tablet is disclosed including a body comprising carbon dioxide source reactable with liquid to produce carbon dioxide gas. The body includes a top side opposite a bottom side, and one or more peripheral sides extending between the top side and the bottom side. The body also includes at least one channel. Each channel extends along one of the top side and the bottom side. Each channel extends in length from a first channel end to a second channel end. Each first and second channel end is located at one of the peripheral sides. Each channel, between its first and second channel ends, is spaced from the peripheral sides. Each channel provides a frangible line of weakness. At least a portion of each channel extends linearly from the channel's first channel end to the channel's second channel end. A beverage carbonating system is also disclosed.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: December 1, 2015
    Assignee: Bonne O Inc.
    Inventor: Darren Hatherell
  • Patent number: 9132082
    Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+ ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: September 15, 2015
    Assignee: Vecta, Ltd.
    Inventors: Aleksey Kostadinov, Tal Atarot, Michael Naveh
  • Patent number: 9044401
    Abstract: Provided is a composition for preventing or treating osteoporosis. The composition contains an ibandronic acid, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and vitamin D. The composition has uniform medicinal effects by minimizing the differences in physical properties between ibandronic acid, or the pharmaceutically acceptable salt thereof, or the hydrate thereof, and vitamin D.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: June 2, 2015
    Assignees: Navipharm Co., Ltd., Dream Pharma Corporation
    Inventors: Sang-Geun Park, Chang-Kyoo Lee, Tae-Won Lee
  • Patent number: 9005660
    Abstract: The present invention relates to immediate release pharmaceutical compositions for oral administration that are resistant to abuse by intake of alcohol. In particular, this disclosure provides immediate release pharmaceutical compositions comprising a polyglycol having a molecular weight of from about 900 to about 17,000 daltons, a drug substance, one or more effervescent agents, and, optionally, one or more disintegrants, such that the composition is formulated to be resistant to abuse by intake of alcohol.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: April 14, 2015
    Assignee: Egalet Ltd.
    Inventors: Peter Holm Tygesen, Jan Martin Oevergaard, Joakim Oestman
  • Patent number: 8956653
    Abstract: The present invention relates to a process for preparing effervescent dosage forms comprising at least one antibiotic of cephalosporin group. The present invention also relates to effervescent formulations and preparations comprising antibiotics of second generation cephalosporin.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: February 17, 2015
    Inventor: Mahmut Bilgic
  • Patent number: 8956652
    Abstract: Effervescent tablets, powders and granules are provided which may be dissolved in water to produce an effervescent rehydrating beverage. The effervescent tablet, powder and granule compositions of the invention deliver electrolytes and carbohydrates at levels that provide hypotonic, isotonic or slightly hypertonic solution when dissolved in water, with acceptable taste.
    Type: Grant
    Filed: September 15, 2005
    Date of Patent: February 17, 2015
    Assignee: Tower Laboratories, Ltd.
    Inventor: Allen H. Rau
  • Publication number: 20140356420
    Abstract: The present invention relates to a micro-particle for extending satiety and controlling blood glucose and lipid levels, comprising a core having the protein extract from sweet potato, an active ingredient layer coated on the core, and a protection layer coated over the active ingredient layer as an external layer, wherein the protein extract from sweet potato contains trypsin inhibitor and glycoprotein. The micro-particle comprising a protein extract from sweet potato can effectively extend satiety, control blood glucose and lipid levels and increase metabolism effectively.
    Type: Application
    Filed: May 30, 2013
    Publication date: December 4, 2014
    Inventor: Chin Yuan Huang
  • Patent number: 8889184
    Abstract: The present invention relates to a pharmaceutical composition for direct oral administration which is very easy to swallow especially for young children, comprising at least one pharmaceutically active compound. The pharmaceutical composition is present in the form of one or more particles. The particles comprise a core containing the active ingredient which has been provided with one or more coatings. The pharmaceutical composition is preferably administered in combination with a powder and/or granules which, when applied to the tongue, spontaneously generate additional saliva. With the extra saliva, the coated particles form a soft, smooth, but mechanically stable surface perceived as pleasant in the mouth within seconds so that they may be swallowed easily and practically in the right quantity with the extra saliva formed.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: November 18, 2014
    Assignee: Losan Pharma GmbH
    Inventors: Peter Gruber, Peter Kraahs
  • Patent number: 8840925
    Abstract: The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: September 23, 2014
    Assignee: Aptalis Pharmatech, Inc.
    Inventors: Gopi M. Venkatesh, Nehal H. Vyas, Michael Gosselin, Jin-Wang Lai
  • Patent number: 8840924
    Abstract: The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug in the drug resin complex relative to an otherwise identical pharmaceutical composition without the resin; and wherein the highly compressible, free-flowing pharmaceutical excipient causes release of the drug-resin complex in the mouth.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: September 23, 2014
    Assignee: NEOS Therapeutics, LP
    Inventors: Mark Tengler, Russell McMahen
  • Publication number: 20140271849
    Abstract: The present disclosure provides an immediate release, abuse deterrent pharmaceutical solid dosage form comprising at least one functional score. In particular, the immediate release, abuse deterrent solid dosage form comprises at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Siva N. Raman, Jae Han Park, Sunil K. Battu, Eric A. Burge, David W. Bogan
  • Patent number: 8821928
    Abstract: Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: September 2, 2014
    Assignee: Egalet Ltd.
    Inventors: Pernille Hoyrup Hemmingsen, Anders Vagno Pedersen, Daniel Bar-Shalom
  • Patent number: 8771648
    Abstract: There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: July 8, 2014
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Bindhumadhavan Gururajan, Farhan Abdul Karim Alhusban, Ian Paul Gabbott, David Bradley Brook Simpson, Dawn Sievwright
  • Patent number: 8765100
    Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of additional pH adjusting substance in combination with the effervescent for promoting the absorption of drugs is also disclosed.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: July 1, 2014
    Assignee: Cephalon, Inc.
    Inventors: Jonathan D. Eichman, John Hontz, Rajendra K. Khankari, Sathasivan Indiran Pather, Joseph R. Robinson
  • Patent number: 8753611
    Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: June 17, 2014
    Assignee: Cephalon, Inc.
    Inventors: Jonathan D. Eichman, John Hontz, Rajendra K. Khankari, Sathasivan Indiran Pather, Joseph R. Robinson
  • Patent number: 8747894
    Abstract: Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: June 10, 2014
    Assignee: Alpex Pharma S.A.
    Inventors: Federico Stroppolo, Gabriele Granata, Shahbaz Ardalan
  • Publication number: 20140141078
    Abstract: A dissolvable tablet is disclosed. The tablet includes a front side, an obverse side and a thickness between the front side and the obverse side. The front side and obverse side have a variation of convex and concave surfaces. The convex and concave surfaces allow for a plurality of dissolvable tablets to be stacked for packaging. Further, the variation of convex and concave surfaces allow for a self-agitation when the dissolvable tablet is dissolved within a liquid.
    Type: Application
    Filed: September 13, 2013
    Publication date: May 22, 2014
    Inventor: Jeffery K. Slaboden
  • Patent number: 8728441
    Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: May 20, 2014
    Assignee: Cephalon, Inc.
    Inventors: Jonathan D. Eichman, John Hontz, Rajendra K. Khankari, Sathasivan Indiran Pather, Joseph R. Robinson
  • Patent number: 8703183
    Abstract: The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.
    Type: Grant
    Filed: December 24, 2010
    Date of Patent: April 22, 2014
    Assignee: Laboratorios Silanes S.A. de C.V.
    Inventor: Jose Manuel FranciscoOchoa Lara
  • Patent number: 8647656
    Abstract: The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: February 11, 2014
    Assignee: Aptalis Pharmatech, Inc.
    Inventors: Gopi M. Venkatesh, Nehal H. Vyas, Michael Gosselin, Jin-Wang Lai
  • Publication number: 20140030326
    Abstract: The present invention relates to water-soluble formulations comprising the active agent dexketoprofen and to a process for production of said formulations. The present invention also relates to pharmaceutical formulations comprising dexketoprofen which is used in symptomatic treatment of mild to moderate pains such as musculoskeletal pains, dysmenorrhoea, toothache, post-operative pains. The formulations are characterized in being in effervescent form.
    Type: Application
    Filed: July 2, 2013
    Publication date: January 30, 2014
    Inventor: Mahmut BILGIC
  • Patent number: 8637076
    Abstract: The present invention relates to tablets containing prednisolone salts and in particular prednisolone sodium phosphates. The dosage forms include ODTs and non-ODTs, effervescent tablets and noneffervescent tablets and tablets meeting certain performance criteria.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: January 28, 2014
    Assignee: Cima Labs Inc.
    Inventors: Walid Habib, Bhaveshkumar Kothari
  • Patent number: 8580300
    Abstract: The invention relates to an effervescent tablet for preparing a mouth rinsing solution, wherein the effervescent tablet exhibits a high release rate of budesonide. A high availability of the active ingredient during use as a mouth rinsing solution on the inflamed mucosa of the upper digestive tract is thereby achieved. The advantage of the formulation according to the invention lies in the bioavailability comparable to oral forms of administration, which allows the formulation to be used safely over an extended period of time.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: November 12, 2013
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolf Wilhelm, Pröls Markus
  • Patent number: 8568775
    Abstract: A medicament tablet containing paracetamol (acetaminophen) as the (or an) active ingredient, and an encapsulated flavorant. The tablet may be swallowed in tablet form or may be dissolved or dispersed in water to form a palatable drink.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: October 29, 2013
    Assignee: Reckitt Benckiser Healthcare (UK) Limited
    Inventor: Paul Frederick Field
  • Publication number: 20130280327
    Abstract: The present invention is directed to oral pharmaceutical forms for rapid disintegration which make it possible to prevent possible misuse of the zolpidem present therein. The present invention thus relates to a zolpidem-based orodispersible tablet formulation intended to prevent abuse of use of the tablet at the expense of a third party.
    Type: Application
    Filed: June 14, 2013
    Publication date: October 24, 2013
    Inventors: Annick MARTINEZ, Olivier ROUGEOT, Yoshikatsu YAGUCHI
  • Publication number: 20130280326
    Abstract: The present invention is directed to oral pharmaceutical forms, the composition of which makes it possible to prevent possible misuse of the active principle present therein. The present invention thus relates to a pharmaceutical composition for oral administration intended to prevent abuse of use at the expense of a third party.
    Type: Application
    Filed: June 14, 2013
    Publication date: October 24, 2013
    Inventors: Annick MARTINEZ, Olivier ROUGEOT, Yoshikatsu YAGUCHI
  • Patent number: 8545889
    Abstract: The present invention comprises a co-processed carbohydrate system, and formulations produced therefrom, which formulations are directly compressible into solid dosage forms, some of which rapidly and completely dissolve or disintegrate in the oral cavity within 60 seconds. The invention also comprises the solid dosage forms produced by directly compressing the co-processed carbohydrate system, some of which, when placed in the oral cavity, shall dissolve or disintegrate, preferably within about 60 seconds.
    Type: Grant
    Filed: June 6, 2006
    Date of Patent: October 1, 2013
    Assignee: SPI Pharma, Inc.
    Inventors: Gary T. Norman, Kalyan S. Nuguru, Arun F. Amin, Sarath Chandar
  • Patent number: 8545858
    Abstract: Porous calcium phosphate implant compositions that approximate the chemical composition of natural bone mineral are provided. In addition to calcium phosphate, the compositions include an effervescent agent to promote the formation of interconnected pores and a cohesiveness agent to maintain the shape and hardness of the hardened composition. When introduced at an implant site, the calcium phosphate compositions are remodeled into bone. Methods for using the calcium phosphate compositions, e.g., to repair or replace bone, are also provided.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: October 1, 2013
    Assignee: Etex Corporation
    Inventors: Aron D. Rosenberg, Laurent D. Gillès de Pélichy, Shrikar Bondre, Michael Strunk
  • Patent number: 8507009
    Abstract: This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time improving the quality of bowel cleansing. The formulations and methods of this invention are particularly useful to cleanse the bowel prior to diagnostic and surgical procedures and can also be employed in lower dosages as a laxative to promote elimination and/or to relieve constipation.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: August 13, 2013
    Assignee: Salix Pharmaceuticals, Inc.
    Inventors: Stephen Skiendzielewski, Martin Rose, Ngoc Do
  • Publication number: 20130202699
    Abstract: The invention relates to a pharmaceutical composition in the form of pourable granules or a chewable tablet containing at least one phosphate binding substance and at least one effervescent agent. The composition may be taken orally without adding water.
    Type: Application
    Filed: October 11, 2011
    Publication date: August 8, 2013
    Applicant: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Kai Strothmann, Friedrich Schulze, Johannes Bartholomaeus, Eva Fries-Schaffner, Astrid Oppermann
  • Patent number: 8486454
    Abstract: The present invention provides a method of attenuating the formation or reducing the severity of neurogenic pain in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of neurogenic pain.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: July 16, 2013
    Assignee: Sessions Pharmaceuticals Inc.
    Inventors: Robert W. Sessions, Alan R. Kahn
  • Patent number: 8394409
    Abstract: A controlled extended drug release technology for the controlled extended release of hydrophobic or hydrophilic drugs or therapeutically active agents consisting of a homogeneous blend of one or more therapeutic agents, gas generators and surrounded by one or more layers of coat made of thermoplastic water insoluble cellulose derivatives, acrylic polymers, superdisintegrants and optionally an oil, antioxidants and electrolytes. The technology platform is capable of releasing therapeutic agents via zero, first or pseudo first order release.
    Type: Grant
    Filed: July 1, 2004
    Date of Patent: March 12, 2013
    Assignee: Intellipharmaceutics Corp.
    Inventors: Isa Odidi, Amina Odidi